AxoGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:04 pm EST
Share
AxoGen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 41.27 million compared to USD 36.96 million a year ago. Net loss was USD 4.09 million compared to USD 4.32 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago.
For the nine months, sales was USD 116.09 million compared to USD 102.42 million a year ago. Net loss was USD 17.82 million compared to USD 23.53 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.56 a year ago. Diluted loss per share from continuing operations was USD 0.42 compared to USD 0.56 a year ago.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.